Long-term follow-up of the ‘London patient’, the second patient to ever achieve sustained HIV remission after ceasing antiretroviral treatment, has suggested that there is no active detectable HIV virus remaining.
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
Take a look behind the scenes of a recent Future Virology article, entitled ‘Update on HIV integrase inhibitors for the treatment of HIV’, as we ask the authors about these drugs for HIV treatment and the future of this field.
The National Institute of Allergy and Infectious Diseases has stopped administering an experimental HIV vaccine in the South Africa HVTN 702 clinical trial, after an independent data and safety monitoring board has found that the vaccine is ineffective at preventing HIV infection.
Take a look at the industry headlines from the last 2 months, including the FDA approval of Ebola vaccine Ervebo,…
Recently, a research collaboration has managed to reverse HIV latency in infected CD4+ T cells in mouse and macaque models, exposing them to the body’s immune response.
Researchers have discovered an association between the spread of HIV and quantity of extracellular vesicles from lactobacilli, suggesting a protective mechanism to inhibit the spread of HIV infection.
Using animal models, researchers have discovered that antibodies can be coaxed into proliferating and targeting HIV.
In this infographic we take a look at the long-acting formulations for HIV prevention and treatment currently in the clinical pipeline – from Phase I to approval.
The WHO have updated their recommendations on HIV testing in order to try and expand treatment coverage and reach the people living with HIV who are not yet diagnosed.
